Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system
Kathryn A. Hjerrild(Research & Development Corporation), Simon J. Draper(University of Oxford), Stine B. Clemmensen(ExpreS2ion Biotechnologies (Denmark)), Willem A. de Jongh(ExpreS2ion Biotechnologies (Denmark)), Daniel G. W. Alanine(University of Oxford), Matthew K. Higgins(University of Oxford), Joseph J. Illingworth(University of Oxford), Kathryn H. Milne(University of Oxford), Katherine E. Wright(Memorial Hermann), Sarah E. Silk(University of Oxford), Alexander D. Douglas(University of Oxford), Jing Jin(Zhejiang Provincial People's Hospital), Geneviève M. Labbé(University of Oxford), Rebecca Brown(University of Oxford), Thomas R. Jørgensen(ExpreS2ion Biotechnologies (Denmark)), Catherine Cherry(University of Oxford), Jennifer M. Marshall(University of Oxford), Rebecca Ashfield(Immunocore (United Kingdom))
Cited by 76
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
|Nature Medicine|2020|643
Severe malaria is associated with parasite binding to endothelial protein C receptor
|Nature|2013|579
Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization
|Scientific Reports|2016|438